ZNF521 Is Correlated with Tumor Immune Cell Infiltration and Act as a Valuable Prognostic Biomarker in Gastric Cancer

Table 1

Relationship of ZNF521 expression with pathological characteristics of gastric cancer.

Clinical parameters	ZNF521
	Low	High	t/χ^2	-value
Age (years)			−1.205	0.229
Gender			0.894	0.201
Male	124 (39.9%)	187 (60.1%)
Female	56 (44.8%)	69 (55.2%)
Location			2.819	<0.01
Proximal	17 (30.9%)	38 (69.1%)
Middle	69 (42.3%)	94 (57.7%)
Distal	94 (43.1%)	124 (56.9%)
Size			6.917	0.006
<5 cm	119 (46.5%)	137 (53.5%)
≥5 cm	61 (33.9%)	119 (66.1%)
Lauren classification			9.616	0.001
Intestinal	108 (48.4%)	115 (51.6%)
Diffuse	72 (33.8%)	141 (66.2%)
Histology classification			4.326	<0.01
Papillary adenocarcinoma	4 (25.0%)	12 (75.0%)
Tubular adenocarcinoma	131 (40.2%)	195 (59.8%)
Mucinous adenocarcinoma	12 (41.4%)	17 (58.6%)
Signet-ring cell carcinoma	33 (50.8%)	32 (49.2%)
Histologic differentiation			1.572	<0.01
Well	6 (46.2%)	7 (53.8%)
Moderately	52 (40.6%)	76 (59.4%)
Poorly	122 (41.6%)	171 (58.4%)
Others	0 (0.0%)	2 (100.0%)
Invasion depth			1.486	<0.01
T1	27 (47.4%)	30 (52.6%)
T2	47 (43.1%)	62 (56.9%)
T3	96 (39.3%)	148 (60.7%)
T4	10 (38.5%)	16 (61.5%)
Lymphatic metastasis			1.200	0.160
No	74 (44.6%)	92 (55.4%)
Yes	106 (39.3%)	164 (60.7%)
Regional lymph nodes			4.297	<0.01
PN0	74 (44.6%)	92 (55.4%)
PN1	57 (41.9%)	79 (58.1%)
PN2	40 (40.4%)	59 (59.6%)
PN3	9 (25.7%)	26 (74.3%)
Distant metastasis			6.631	0.007
No	164 (43.7%)	211 (56.3%)
Yes	16 (26.2%)	45 (73.8%)
TNM stages			6.783	<0.01
I	42 (46.7%)	48 (53.3%)
II	45 (43.3%)	59 (56.7%)
III	74 (42.8%)	99 (57.2%)
IV	19 (27.5%)	50 (72.5%)

Bold values indicate that statistical significance was set at P < 0.05.